Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21060961 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060920 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060903 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060913 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060885 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060973 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060970 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060923 | 1.00 | LMNA (0.45) | LMNAMAPK1SMN1; SMN2NPSR1GPR84 | |
| SCHEMBL21060948 | 0.90 | HTR6 (0.40) | LMNAMAPK1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL21060935 | 0.82 | HCAR2 (0.54) | GPR84HCAR2GHSRHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL SA (ES) | 2021-07-22 | — | — | US | disclosed |
| CN-111886230-A | Pyrrole derivatives as ACC inhibitors | 阿尔米雷尔有限公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3724182-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | Almirall S.A. (ES) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019115405-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ALMIRALL, S.A. (ES) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220328-A1 | PYRROLE DERIVATIVES AS ACC INHIBITORS | ACACA, ACACB, PCCA | LMNA 4141/4885MAPK1 2388/4885SMN1; SMN2 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.